Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971345 | 0.86 | CHRNA7 (0.56) | CHRNA7CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL18204352 | 0.84 | CHRNA7 (0.53) | CHRNA7CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL18440369 | 0.80 | NPC1 (0.43) | CHRNA7ALDH1A1 | |
| SCHEMBL5968489 | 0.78 | CHRNA7 (0.43) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL5968583 | 0.77 | CHRNA7 (0.43) | CHRNA7 | |
| SCHEMBL5968444 | 0.77 | CHRNA7 (0.43) | CHRNA7 | |
| SCHEMBL30646221 | 0.77 | KDM4E (0.47) | ADRA1AKDM4EALDH1A1 | |
| SCHEMBL27354007 | 0.76 | CHRNA7 (0.39) | CHRNA7CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL5968380 | 0.75 | CHRNA7 (0.41) | CHRNA7CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4795807 | 0.75 | ADRA1A (0.47) | CHRNA7ADRA1AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850120-A | Preparation method of alcohol alpha-carbon hydrogen bond alkylated compound | 浙江工业大学 | 2023-03-28 | — | — | CN | claimed |
| US-5236931-A | Treating anxiety, psychosis, cognitive dysfunction, migrane, cluster headache, trigeminal neuralgia emesis and impaired gastric motility | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-08-17 | — | — | US | claimed |
| CN-115850120-A | Preparation method of alcohol alpha-carbon hydrogen bond alkylated compound | 浙江工业大学 | 2023-03-28 | — | — | CN | disclosed |
| US-20110178118-A1 | PALONOSETRON FOR THE TREATMENT OF CHEMOTHERAPY INDUCED EMESES | HELSINN HEALTHCARE SA (CH) | 2011-07-21 | — | — | US | disclosed |
| EP-1596862-B1 | USE OF PALONOSETRON FOR TREATING POST-OPERATIVE NAUSEA AND VOMITING | HELSINN HEALTHCARE SA (CH) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258367-A2 | Use of palonosetron for treating post-operative nausea and vomiting | Helsinn Healthcare S.A. (CH) | 2010-12-08 | — | — | EP | disclosed |
| EP-2205241-A1 | POLO-LIKE KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-2205603-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Cyclacel Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009040556-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2009-04-02 | — | — | WO | disclosed |
| US-20060079545-A1 | Palonosetron for the treatment of chemotherapy induced emeses | HELSINN HEALTHCARE SA (CH) | 2006-04-13 | — | — | US | disclosed |
| US-5723103-A | ALTERED 5-HT-3 OR NEUROTRANSMITTER RECEPTOR FUNCTION | VANDERBILT UNIVERSITY (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1996017630-A9 | SUBSTITUTED BENZAMIDES AND RADIOLIGAND ANALOGS AND METHODS OF USE | — | 1996-08-08 | — | — | WO | disclosed |
| WO-1996017630-A1 | SUBSTITUTED BENZAMIDES AND RADIOLIGAND ANALOGS AND METHODS OF USE | VANDERBILT UNIVERSITY (US) | 1996-06-13 | — | — | WO | disclosed |
| US-5273972-A | [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5236931-A | Treating anxiety, psychosis, cognitive dysfunction, migrane, cluster headache, trigeminal neuralgia emesis and impaired gastric motility | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-08-17 | — | — | US | disclosed |
| US-5236931-A | Treating anxiety, psychosis, cognitive dysfunction, migrane, cluster headache, trigeminal neuralgia emesis and impaired gastric motility | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-08-17 | — | — | US | disclosed |
| US-5084460-A | Psychological disorders, anxiolytic agents and cognition activators | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-01-28 | — | — | US | disclosed |
| US-5084460-A | Psychological disorders, anxiolytic agents and cognition activators | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-01-28 | — | — | US | disclosed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079545-A1 | Palonosetron for the treatment of chemotherapy induced emeses | HTR3A, HTR3C, HTR3B | CHRNA7 409/4885CHRM2 502/4885CHRM1 795/4885 |
| US-20110178118-A1 | PALONOSETRON FOR THE TREATMENT OF CHEMOTHERAPY INDUCED EMESES | HTR3A, HTR3C, HTR3B | CHRNA7 409/4885CHRM2 502/4885CHRM1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.